RT Journal Article
SR Electronic
T1 Genomics-informed Neuropsychiatric Care for Neurodevelopmental Disorders: Results from A Multidisciplinary Clinic
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2024.05.08.24307074
DO 10.1101/2024.05.08.24307074
A1 Besterman, Aaron D.
A1 Adams, David J.
A1 Wong, Nicole R.
A1 Schneider, Benjamin N.
A1 Mehta, Sunil
A1 DiStefano, Charlotte
A1 Wilson, Rujuta B.
A1 Martinez-Agosto, Julian A.
A1 Jeste, Shafali S.
YR 2024
UL http://medrxiv.org/content/early/2024/05/09/2024.05.08.24307074.abstract
AB Background Patients with neurodevelopmental disorders (NDDs) have high rates of neuropsychiatric comorbidities that can be highly impairing and treatment refractory. Genomic medicine may help guide care, as pathogenic variants are identified in up to 50% of patients with NDDs. We evaluate the impact of a genomics-informed, multidisciplinary, neuropsychiatric specialty clinic on the diagnosis and management of patients with NDDs.Methods We performed a retrospective study of 316 patients from the UCLA Care and Research in Neurogenetics Clinic, a genomics-informed multidisciplinary clinic composed of psychiatry, neurology, medical genetics, psychology, and social work.Results We observed high rates of psychiatric and medical comorbidity. Among the 246 patients that underwent genetic testing, 41.8% had a pathogenic or likely pathogenic (P/LP) variant. Patients had 62 different genetic diagnoses, with 12 diagnoses shared by two or more patients, including Duplication 15q syndrome (9.18%), Tuberous Sclerosis Complex (3.48%), and Angelman syndrome (1.27%), while 50 diagnoses were found in only single patients. Genetic diagnosis resulted in direct changes to clinical management in all patients with a P/LP variant, including high rates of cascade testing (30.6%), family counseling (22.2%), medication changes (13.9%), clinical trial referral (2.8%), medical surveillance (30.6%), and specialty referrals (69.4%).Conclusions A genomics-informed model can provide significant clinical benefits to patients with NDDs, directly impacting management across multiple domains for most diagnosed patients. As precision treatments for NDDs advance, establishing a genetic diagnosis will be critical for proper management. With the growing number of rare neurogenetic disorders, clinician training should emphasize core principles of genomic medicine over individual syndromes.Competing Interest StatementS.M. acted as a paid consultant to Mirium Pharmaceuticals. All other authors declare no competing interests.Funding StatementA.D.B. was supported by an NIGMS T32 Medical Genetics Training Grant 2T32GM008243-31 and the UCLA Savant Fellowship in Neurodevelopmental Genetics. R.B.W. is supported by NICHD K23HD099275. R.B.W. and J.A.M-A. are supported by the Health Resources and Services Administration (HRSA) of the U.S. Department of Health and Human Services (HHS) under the Autism Intervention Research Network on Physical Health (AIR‐P) grant, UT2MC39440. The information, content and/or conclusions are those of the authors and should not construed as the official position or policy of, nor should any endorsements be inferred by HRSA, HHS or the U.S. Government. The CARING Clinic received additional financial support from the UCLA Intellectual and Developmental Disabilities Research Center.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Research approval was granted by the UCLA Medical Institutional Review Board 3. One-hundred-ten patients and/or their legal guardians provided informed consent for prospective collection of clinical data (UCLA Institutional Review Board (IRB) #: 14-001908). Patient assent was obtained when feasible. With an IRB-approved waiver of consent, the charts of an additional 206 patients were retrospectively reviewed (UCLA IRB#: 19-000121).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesThe datasets generated and/or analyzed during the current study are not publicly available due to patient privacy laws but are available from the corresponding author on reasonable request.ADIarea deprivation indexASDautism spectrum disordersCARINGcare and research in neurogeneticsGDDglobal developmental delayIDintellectual disabilityIRBinstitutional review boardNDDneurodevelopmental disorderP/LPpathogenic or likely pathogenicPNESpsychogenic nonepileptic seizuresSESsocioeconomic statusSVIsocial vulnerability indexUCLAUniversity of California Los Angeles